GILD - Gilead Sciences, Inc.
| Previous Close | 65.78 |
| Open | 65.77 |
| Bid | 66.36 x 1800 |
| Ask | 66.73 x 2200 |
| Day's Range | 65.60 - 67.22 |
| 52 Week Range | 60.32 - 79.61 |
| Volume | 6,660,945 |
| Avg. Volume | 7,022,007 |
| Market Cap | 84.38B |
| Beta (3Y Monthly) | 1.20 |
| PE Ratio (TTM) | 14.64 |
| EPS (TTM) | 4.53 |
| Earnings Date | Jul 23, 2019 - Jul 29, 2019 |
| Forward Dividend & Yield | 2.52 (3.87%) |
| Ex-Dividend Date | 2019-06-13 |
| 1y Target Est | 80.51 |
- Motley Fool•5 hours ago
Better Buy: Vertex Pharmaceuticals vs. Galapagos
Two rising biotech stocks. One clear long-term winner.
- Motley Fool•2 days ago
Who Had the Better Quarter: Gilead Sciences or Amgen?
Here's which one of these large-cap biotechs put up the best numbers in the first quarter.
Bloomberg•3 days agoA Leading HIV Drug Is Way Overpriced in the U.S.
O’Day faced questioning at a Thursday hearing over the high price of Truvada, a medicine approved to treat HIV and prevent infection. Activists claim that the price prevents at-risk people from accessing the drug and has helped keep infection rates high. Truvada’s annual list price has nearly tripled in the U.S. to more than $20,000 over the past 15 years. News broke in April that the government is reviewing patents on Truvada’s preventative use that could entitle taxpayers to millions in royalties.
- Zacks•3 days ago
Agios' Tibsovo Meets Endpoint in Cholangiocarcinoma Study
Agios' (AGIO) Tibsovo achieves the primary goal in a late-stage development that examined it for the previously treated IDH1 mutant cholangiocarcinoma. Shares rise in after-hours trading.
- MoneyShow•4 days ago
Gilead- A Top Biotech for Turnaround Investors
Gilead Sciences (GILD) is a major biopharmaceuticals producer focusing on life-threatening diseases. Founded in 1987 by Michael Riordan, a 29-year-old medical doctor, Gilead has grown to over $22 billion in revenues, notes George Putnam, editor of The Turnaround Letter.
- American City Business Journals•4 days ago
Influential Women 2019: Top CFO Robin Washington pushes beyond her comfort zone
The Gilead CFO is using her career and platform to enable the next generation to come up and succeed.
- Business Wire•4 days ago
Kite to Present New Data From Leading Cell Therapy Portfolio at ASCO 2019
-- New Safety Data Involving Steroid Use and New Subpopulation Analyses from Pivotal ZUMA-1 Trial to Provide Greater Understanding of Yescarta® in Patients with Relapsed or Refract
- Zacks•4 days ago
Mallinckrodt Ends Enrollment in Phase III for Terlipressin
Mallinckrodt (MNK) concludes enrollment in the phase III study on terlipressin, currently under development for treating adult patients with Hepatorenal Syndrome Type 1.
- Zacks•4 days ago
Biotech Stock Roundup: FDA Nod for REGN's Eylea in DR, Tie-Ups & Other Updates
Key highlights of the past week are regulatory and pipeline updates by the leading biotech companies.
- CNBC•5 days ago
Lawsuit accuses Gilead of propping up cost of lifesaving HIV treatments by blocking generic competition
Pharmaceutical giant Gilead Sciences engaged in a "long-running scheme" to block generic competition of its combination drug "cocktails" to treat HIV. The complaint, filed in the U.S. District Court in San Francisco, names drugmakers Bristol-Myers Squibb and Johnson & Johnson subsidiary Janssen Pharmaceuticals as co-defendants. The plaintiffs in the suit claim that Gilead's actions caused the cost of the life-saving treatment to rise.
- Zacks•6 days ago
GILD vs. ILMN: Which Stock Is the Better Value Option?
GILD vs. ILMN: Which Stock Is the Better Value Option?
- Market Exclusive•6 days ago
Market Morning: Kudlow Cracks, Brexiters Rage, Gilead Butters Up FDA, Philip Morris Backtracks
Buy Services, Sell Goods, Says Goldman Sachs If Tariff War Explodes The people at Goldman Sachs (NYSE:GS) may know a bit about trading, or maybe not, but either way, they’re saying to sell goods stocks and buy services stocks if the Chinese retaliate to the Trump Administration’s latest move to jack up tariffs on $200 […]The post Market Morning: Kudlow Cracks, Brexiters Rage, Gilead Butters Up FDA, Philip Morris Backtracks appeared first on Market Exclusive.
- Motley Fool•7 days ago
Is It Finally Time to Buy Gilead Sciences?
Its been a tough few years for investors in this big-cap biotech, but signals are emerging that better days are ahead.
- Zacks•9 days ago
Global Blood (GBT) Reports Narrower-Than-Expected Loss in Q1
Global Blood (GBT) reports narrower-than-expected loss in the first quarter of 2019.
- Zacks•9 days ago
Agenus (AGEN) Q1 Earnings Beat Estimates, Revenues Miss
Agenus' (AGEN) earnings beat estimates in the first quarter of 2019. Sales marginally miss the same.
- Zacks•9 days ago
PDL BioPharma (PDLI) Q1 Earnings Top Mark, Revenues Rise Y/Y
PDL BioPharma's (PDLI) earnings exceed estimates in the first quarter of 2019. Higher royalty rights as well as product sales lead to a marginal spurt in year-over-year revenues
- Zacks•9 days ago
Intrexon (XON) Reports In-Line Q1 Loss, Misses on Revenues
Intrexon (XON) reports in line loss in the first quarter of 2019. Also, sales miss estimates.
- CNBC•9 days ago
Drugmaker Gilead reaches multiyear agreement with White House to donate HIV prevention med
Gilead will donate its PrEP medication Truvada, which is used to reduce the risk of HIV infection and usually sells for $1,600 to $2,000 a month in the United States.
- MarketWatch•10 days ago
Gilead to donate HIV medication for up to 200,000 Americans a year
The Health and Human Services Department announced Thursday that California-based Gilead Sciences Inc. has agreed to donate medications that reduce the risk of HIV transmission for up to 200,000 people a year.
- Associated Press•10 days ago
Drugmaker will donate meds for US push to end HIV epidemic
WASHINGTON (AP) — The Health and Human Services Department announced Thursday that California-Based Gilead Sciences Inc. has agreed to donate medications that reduce the risk of HIV transmission for up to 200,000 people a year.
- Zacks•10 days ago
Horizon Therapeutics' (HZNP) Q1 Earnings Beat Estimates
Horizon Therapeutics' (HZNP) sales beat estimates in the first quarter of 2019, primarily owing to strong performance of Krystexxa, Ravicti, Procysbi and Rayos.
- Business Wire•10 days ago
Gilead Sciences to Provide Free Truvada for PrEP® to Support U.S. Initiative to End the HIV Epidemic
Gilead Sciences, Inc. (GILD) today announced that it will donate Truvada for PrEP® (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg tablets) to the U.S. Centers for Disease Control and Prevention (CDC) in support of national efforts to help prevent HIV and end the epidemic. This medication donation is among the largest ever in the United States and is part of Gilead’s broader ongoing initiatives to help ensure that everyone who can benefit from PrEP is able to access it. Gilead will provide to CDC up to 2.4 million bottles of Truvada® annually for uninsured Americans at risk for HIV.
- Zacks•10 days ago
Amicus' (FOLD) Earnings & Revenues Miss Estimates in Q1
Amicus (FOLD) reports wider-than-expected loss in the first quarter of 2019. Also, sales miss estimates.
- Zacks•10 days ago
Nektar (NKTR) Q1 Earnings & Revenues Beat, Decline Y/Y
Nektar's (NKTR) earnings and sales beat estimates in the first quarter. The company is progressing well with its pipeline candidates.
- Zacks•10 days ago
Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Beat
Intercept's (ICPT) Q1 revenues top estimates on strong Ocaliva sales, driven by sales force expansion.
